Stock info Newron Pharmaceuticals | Filter  Basic-Info

Newron Pharmaceuticals

The past year was a profitable year for the Newron Pharmaceuticals investors

The period between December 2015 and December 2016 was a loss-making period for the investors in Newron Pharmaceuticals. The stock lost around 31 percent. Over the past 5 years the stock rose a massive 619,23 percent. Newron Pharmaceuticals's revenues between 2011 and 2015 were very fluctuating and moved between 8,91 million euros and 2,28 million euros. Newron Pharmaceuticals's net incomes between 2011 and 2015 were very volatile through the time and moved between -6,45 million euros and -18,44 million euros.

The period from 2006 till the end of 2016 the international sector gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The Italian company didn't pay out any dividends (in the past 5 years).

Newron Pharmaceuticals financed with lots of debt

Last year the balance sheet of the Italian company was worth 44,38 million euros. Of the total balance sheet 7,27 million euros (16,38 percent) was financed by debt.

At the end of 2015 the Italian company had around 13,72 million stocks listed on the exchanges.

At this page you find all Newron Pharmaceuticals's financial reports. More information about Newron Pharmaceuticals can be found it's website. .